- Alvotech ( NASDAQ: ALVO ) on Wednesday said it had started a pharmacokinetic study for its AVT03 biosimilar to Amgen's ( AMGN ) bone disease drugs Prolia and Xgeva.
- ALVO said the clinical study will assess the pharmacokinetics, safety and tolerability of AVT03 vs. Prolia in healthy male adults.
- Amgen's ( AMGN ) Prolia and Xgeva drugs are both blockbusters, bringing in worldwide sales of $3.25B and $2.02B, respectively, in 2021.
- AVT03 is the fourth product in Iceland-based Alvotech's ( ALVO ) portfolio to enter clinical studies.
- The biotech earlier in July started a confirmatory clinical trial for its AVT06 biosimilar candidate to Regeneron's ( REGN ) blockbuster eye injection Eylea.
- ALVO stock -0.9% to $6.75 in early trading.
For further details see:
Alvotech starts pharmacokinetic study for its biosimilar to Amgen's bone disease drugs